Xiaofan Liu

机构：Chinese Academy of Medical Sciences & Peking Union Medical College, University of Jinan, Institute of Hematology & Blood Diseases Hospital, Qilu Hospital of Shandong University · ORCID：0000-0002-9911-4491

发表论文 33 篇 · 总被引 130 次 · h-index 6

代表论文

• Anti-CD38 monoclonal antibody CM313 for primary immune thrombocytopenia: multicentre, randomised, placebo controlled, phase 2 trial (2025 · BMJ · 被引 8)
• Dopant compensation in component-dependent self-doped Cs2SnI6 thin films grown with PLD at room temperature (2024 · Journal of Material Science and Technology · 被引 4)
• Daratumumab in patients with immune thrombocytopenia: a single-center, open-label, phase 2 trial (2026 · EClinicalMedicine · 被引 3)
• Buried Interface Toughening and Multi-Site Defect Passivation for Thermally Stable Wide-Bandgap Perovskite Solar Cells (2026 · ACS Applied Materials & Interfaces · 被引 3)
• Reduced Platelet Activation in Triple-Negative Essential Thrombocythemia Compared with JAK2V617F -Mutated Essential Thrombocythemia (2024 · Clinical Cancer Research · 被引 3)
• Phase 1 pilot study for hemophilia-A: AAV8 vector with prophylactic tacrolimus-glucocorticoid achieves therapeutic FVIII activity (2026 · Signal Transduction and Targeted Therapy · 被引 2)